Clinical Trials - TOVX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT05673811Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerCOMPLETEDPHASE22023-01-102025-03-282025-03-28
NCT05045833Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020COMPLETEDPHASE12021-10-182022-03-212022-02-22
NCT04815993Pharmacokinetics, Safety, and Tolerability of SYN-020COMPLETEDPHASE12021-03-222021-09-302021-05-18
NCT04692181SYN-004 Safety and Tolerability in Allo-HCT SubjectsACTIVE_NOT_RECRUITINGPHASE1, PHASE22021-02-152026-122025-12
NCT02563106A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTICOMPLETEDPHASE22015-102016-112016-11
NCT02493036A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-CCOMPLETEDPHASE22015-102015-122015-12
NCT02473640A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an IleostomyCOMPLETEDPHASE1, PHASE22015-062016-042016-04
NCT02495623A Study of the Effect of SYN-010 on Subjects With IBS-CCOMPLETEDPHASE22015-062015-112015-10
NCT02419001A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning IleostomyCOMPLETEDPHASE1, PHASE22015-032015-102015-09
NCT02045602Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid TumorsCOMPLETEDPHASE12014-012020-012019-05
NCT02045589A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic CancerCOMPLETEDPHASE12014-012018-092016-10